ESMO Virtual Congress 2020 Around the Corner: All Eyes On Lung Cancer
The ESMO Virtual Congress 2020, September 19-21, will present promising new developments aimed at...
Read More
Meeting Coverage
ESMO 2020: Tumor-Agnostic Data from STARTRK-1 and STARTRK-2
Two sets of CNS efficacy data from integrated analyses of the pivotal phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented, including a poster presentation evaluating the efficacy of...
Read MoreESMO 2020: Analysis of Long-Term Survivors in the IMpower133 Trial for ES-SCLC
Results from an exploratory analysis of characterization of long-term survivors (LTS), defined in the study as people who survived for longer than 18 months following randomization, in the IMpower133 trial will be presented in a...
Read More
ACTRIMS-ECTRIMS: Thyroid Disorders Don’t Affect MS Control
Thyroid AEs did not diminish alemtuzumab efficacy Adverse thyroid events occur frequently among...
Read More
ACTRIMS-ECTRIMS: Advantages Seen for Ozanimod over Teriflunomide
Safety modeling favors ozanimod Patients diagnosed with multiple sclerosis appear to have fewer...
Read MoreFinal Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Bevacizumab
final data from the FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and bevacizumab (Avastin® )in patients with folate receptor alpha (FRα)-positive recurrent, platinum-sensitive...
Read More
ACTRIMS-ECTRIMS: Alemtuzumab Slows Brain Atrophy in MS Patients
Benefit observed in patients with or without disease activity Among multiple sclerosis patients...
Read More
MSVirtual2020: Anticipated Efficacy Results from Phase IV MAGNIFY-MS Study
Efficacy results from the Phase IV MAGNIFY-MS study and its impact on a reduction in mean combined...
Read More
Upcoming MSVirtual2020: Virtual Joint ACTRIMS-ECTRIMS Meeting
MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis...
Read More
ACTRIMS-ECTRIMS: Anticipated Results from ASCLEPIOS Phase III
New efficacy and safety data on ofatumumab (Kesimpta), the first and only self-administered,...
Read More
ACTRIMS-ECTRIMS: Progressive Forms of MS and Disease-Modifying Therapies
Health Union has been accepted to present research, in the form of two poster presentations,...
Read More
ACTRIMS-ECTRIMS: The Potential of Brain-Penetrant BTK Inhibitors
This year, MSVirtual2020 (ACTRIMS/ECTRIMS) congress will feature new data relating to tolebrutinib...
Read More
ACTRIMS-ECTRIMS: Program at a Glance
Download the MSVirtual2020 Program at a Glance schedule (PDF)
Read More
ESC: Pharmacologic Treatments for Heart Failure Abound, But Uptake Lags
As researchers tout outcomes, Rx lags and a new drug is on the horizon It’s been six years...
Read More
ESC 2020: HFpEF Again Proves to Be Treatment-Resistant
PARALLAX finds biomarker benefit for ARNI, but fails to show functional benefit Heart failure with...
Read More
Patients Let Cardiac, Neuro Care Needs Slide During Pandemic
U.S. and U.K. researchers report dip in services, including TIA admissions Since the Covid-19...
Read More
ESC 2020: Early Is Better for Rhythm Control in Afib
EAST-AFNET 4 findings suggest optimum treatment window is measured in months In medicine, results...
Read More
ESC 2020: EMPEROR-Reduced Trial: Empagliflozin Reduces CV Death by 25%
Findings confirm DAPA-HF ’no fluke’ Adding empagliflozin to standard heart failure treatment...
Read More
ESC 2020: Lowering Blood Pressure Appears to Benefit Most People
Even normotensive people can reduce risks Patients with heart disease or who are at risk of...
Read More
Conference Highlights: AAIC 2020
New research was presented at AAIC 2020, the virtual Alzheimer’s Association International...
Read More